Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake
https://doi.org/10.18087/cardio.n951
Abstract
The thematic review presents modern solutions using oral anticoagulants with a focus on direct coagulation factor X inhibitors. It contains information about the pharmacodynamics and pharmacokinetics of apixaban and rivaroxaban against the background of different drug intake regimens - twice and once per day. There are shown studies of concentration dynamics and the corresponding functional response, measured using the integral method - the thrombin generation test, which is widely used in scientific research to describe hemostatic processes based on an objective quantitative assessment of the thrombin formation – a key coagulation cascade serine protease. The logical relationship between the pharmacodynamics of anticoagulant action and the clinical presentation of the effectiveness and safety of drugs is traced. The review provides links to actual literature and current clinical guidelines.
About the Author
T. V. Vavilova
Almazov National Medical Research Centre
Russian Federation
Akkuratova 2, St. Petersburg 197341
Russian Federation
Akkuratova 2, St. Petersburg 197341
References
1. Novikova TN. A new era of anticoagulant therapy in patients with non-valvular arterial fibrillation. Effective Pharmacotherapy. 2013; 33:42–50.
2. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines on management of atrial fibrillation developedin collaboration with EACTS. Russian Journal of Cardiology. 2017;22(7):7–86. DOI: 10.15829/1560-4071-2017-7-7-86
3. Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing G-J, Harjola V-P et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2019; ehz405. [Epub ahead of print]. DOI: 10.1093/eurheartj/ehz405
4. Register of medicines of Russia. Dabigatrani etexilas – description of the substance, instructions, use, contraindications and formula. [Internet] Available at: https://www.rlsnet.ru/mnn_index_id_5498.htm
5. Register of medicines of Russia. Rivaroxabanum – description of the substance, instructions, use, contraindications and formula. [Internet] Available at: https://www.rlsnet.ru/mnn_index_id_5514.htm
6. Register of medicines of Russia. Apixabanum- description of the substance, instructions, use, contraindications and formula. [Internet] Available at: https://www.rlsnet.ru/mnn_index_id_6095.htm
7. Mani H, Lindhoff-Last E. New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design, Development and Therapy. 2014; 8:789–98. DOI: 10.2147/DDDT.S45644
8. Dolgov V.V., Vavilova T.V., Svirin P.V. Laboratory diagnosis of hemostatic disorders. -Tver: Triada;2019. - 400 p. ISBN 978-5-94789-877-4
9. Douxfils J, Ageno W, Samama C-M, Lessire S, ten Cate H, Verhamme P et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis. 2018;16(2):209–19. DOI: 10.1111/jth.13912
10. Tripodi A. Thrombin Generation Assay and Its Application in the Clinical Laboratory. Clinical Chemistry. 2016;62(5):699–707. DOI: 10.1373/clinchem.2015.248625
11. Hillarp A, Gustafsson KM, Faxälv L, Strandberg K, Baghaei F, Fagerberg Blixter I et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. Journal of Thrombosis and Haemostasis. 2014;12(9):1545–53. DOI: 10.1111/jth.12649
12. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. New England Journal of Medicine. 2010; 363(26): 2487–98. DOI: 10.1056/NEJMoa1006885
13. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clinical Pharmacology & Therapeutics. 2005;78(4):412–21. DOI: 10.1016/j.clpt.2005.06.011
14. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects: Apixaban multiple dose safety, PK and PD. British Journal of Clinical Pharmacology. 2013;76(5):776–86. DOI: 10.1111/bcp.12106
15. Frost C, Song Y, Barrett YC, Wang J, Pursley J, Boyd R et al. A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban. Clinical Pharmacology: Advances and Applications. 2014; 6:179–87. DOI: 10.2147/CPAA.S61131
16. Kreutz R, Persson PB, Kubitza D, Thelen K, Heitmeier S, Schwers S et al. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study. Journal of Thrombosis and Haemostasis. 2017;15(10):2017–28. DOI: 10.1111/jth.13801
17. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2011;365(11):981–92. DOI: 10.1056/NEJMoa1107039
18. Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine. 2010;363(26):2499–510. DOI: 10.1056/NEJMoa1007903
Review
For citations:
Vavilova T.V. Anticoagulant activity of direct factor Xa inhibitors as a tool to ensure the effectiveness and safety of drugs intake. Kardiologiia. 2019;59(11S):28-35. (In Russ.) https://doi.org/10.18087/cardio.n951
Views:
4783
Email this article 
Post a Comment 
